News
on
|
News Release
Potential curative therapies may help reduce the burden, but are also costly Americans ages 64 and younger with commercial health insurance who live with sickle cell disease (SCD) pay almost four times more in out-of-pocket medical costs over their lifetimes, a total of $44,000, compared to people living without the disease. And insurers pay $1.7...
|
Media Availability
For Rare Disease Day 2022, NHLBI experts available to discuss rare heart, lung, and blood conditions
WHAT: To raise awareness about Rare Disease Day on February 28, researchers from the National Heart, Lung, and Blood Institute (NHLBI) are available to share updates about research designed to support people living with rare or uncommon heart, lung, and blood conditions. WHY: In the U.S., a condition is considered rare if it affects less than 200...
|
Research Feature
“Look at that! Life!” said Deidra Flowers-Williams , a sickle cell disease patient, as she held up a tube with stem cells donated by her sister, Tanisha Flowers. It was just minutes before doctors at the NIH Clinical Center would use the cells – extracted from her sister’s bone marrow – for a transplant they hoped would cure the devastating blood...
Credit:
Hemex Health
|
Research Feature
About 20 years ago, researchers excitedly announced the coming of so-called lab-on-chip devices that could revolutionize medicine. At the time, people marveled at the possibilities: The devices would take the capabilities of a large biochemistry lab and shrink them to a platform the size of a cell phone or smaller. With help from a portable scanner...
|
Research Feature
At St. Louis Children’s Hospital in Missouri, a 12-year-old boy waiting in an exam room held a tablet as he scrolled through a trivia game about sickle cell disease (SCD) – an inherited blood disorder that had brought him to the hospital for a regular visit. As he played the game, he won a badge each time he answered a question right. But happily...
|
News Release
Finding could lead to new ways to reduce complications from painful red blood cell disorder Researchers have discovered that DNA from the mitochondria - the cell’s “powerhouses” - acts as a danger signal in the body and triggers inflammation in people with sickle cell disease. A better understanding of mitochondrial DNA, long known to circulate in...
|
Research Feature
The coronavirus pandemic has caused tragedy and turmoil for millions of people around the world, but it has been particularly unkind to one group whose health journey is often overlooked: Those with sickle cell disease. A growing number of studies now suggest that people with this painful genetic blood disorder who also are infected with SARS-CoV-2...
|
Research Feature
A new smartphone app could be a boon for adolescents, young adults When the Food and Drug Administration (FDA) approved the drug hydroxyurea to help reduce the excruciating pain suffered by people with sickle cell disease, the health care community was hopeful. The year was 1998, and the prospect of a drug that could offer significant relief from...
|
Research Feature
Multi-institute NIH study suggests that the HPV vaccine could protect women against new HPV infections after stem cell transplantation The human papillomavirus (HPV) vaccine provides a safe, robust immune response against HPV in reproductive-aged women who have had a stem cell transplant. The results from the small study published in the Journal of...
|
News Release
Fresh red blood cell transfusions do not help critically ill children more than older cells NIH-funded finding may alter policies at hospitals where fresh red cells are preferentially used Researchers have found that transfusions using fresh red blood cells—cells that have spent seven days or less in storage—are no more beneficial than older red...
|
News Release
Initial investment aims to advance accessible and scalable candidate interventions into clinical trials within 10 years The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease (SCD) and HIV. The Bill & Melinda Gates...
|
Research Feature
En el 2000, Mercy Mendoza, a los 3 años, languidecía con una enfermedad misteriosa. Su abuela, desesperanzada, compró un sitio donde enterrarla en el pueblito de Honduras donde vivían. La hinchazón, el dolor y la inmovilidad estaban erosionando rápidamente su salud. Finalmente, un médico que había estudiado en los Estados Unidos reconoció su...
|
Research Feature
In 2000, a mysterious disease was making 3-year-old Mercy Mendoza so ill that her grandmother bought a burial plot for her in the little town in Honduras where they lived. Swelling, pain, and immobility were fast eroding her health. Finally, a doctor who had been trained in the United States recognized her condition: It was sickle cell disease, an...
|
Research Feature
When CBS’s 60 Minutes aired the compelling story of a Florida woman whose severe sickle cell disease symptoms were alleviated with a cutting edge gene therapy technique, people listened. A lot of them. The treatment happened at the National Institutes of Health, and since the showcasing of its dramatic success, NIH has been responding to scores of...
|
Research Feature
A conversation with Dr. Kolapo Oyebola It is not lost on Kolapo Oyebola, Ph.D., that half the sickle cell disease cases worldwide can be found in his native Nigeria. This tragic fact, said the National Institutes of Health (NIH) postdoctoral fellow, has long been top of mind—and he is bent on doing something about it. Something big. He wants to...
|
Research Feature
Soon after birth, a baby in the United States is tested for sickle cell disease, the often-devastating genetic blood disorder affecting more than 100,000 Americans and 20 million of people worldwide. If positive, that newborn typically begins a course of treatment that can greatly prolong life and help stave off complications of the disease. But in...
|
Media Availability
WHAT: A scientist from the National Institutes of Health will present promising, early results from a human clinical trial testing a novel gene replacement therapy in people with severe sickle cell disease. Preliminary findings suggest that the approach has an acceptable level of safety and might help patients consistently produce normal red blood...
|
Research Features
More than 100,000 people in the United States and an estimated 20 million worldwide suffer from sickle cell disease, a group of inherited, often life-threatening blood disorders that wreak havoc on the body. Mainly affecting African-Americans, Hispanics and Asians, the disease is caused by a [embed type:node embed_type:glossary_term id:84178 plural...
|
Research Feature
When the NHLBI announced the launch of the Cure Sickle Cell Initiative on September 13, many in the sickle cell disease community responded with enthusiasm. Patients, family members, and advocates took to social media and other channels to say they are ready to do their part, starting with spreading the news about the initiative to their neighbors...